Nicox SA

ALCOX

FR0013018124

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:29:49 2024-04-19 am EDT			5-day change	1st Jan Change
0.381 ^EUR	+1.74%		-1.42%	-13.80%

Feb. 28	Nicox, BlackRock Sign Deal for Debt Restructuring	MT
Feb. 28	Nicox Names Chief Business Officer as New CEO	MT

Nicox S.A. Reports Revenue Results for the First Quarter of 2021

April 19, 2021 at 01:30 am EDT

Nicox S.A. reported revenue results for the first quarter of 2021. For the period, the company reported net revenue of €0.6 million compared to €1.7 million a year ago.

Latest news about Nicox SA

Nicox, BlackRock Sign Deal for Debt Restructuring	Feb. 28	MT
Nicox Names Chief Business Officer as New CEO	Feb. 28	MT
Nicox SA Announces CEO Changes	Feb. 28	CI
Nicox, Kowa Team Up to Develop, Commercialize NCX 470 Eyedrop in Japan	Feb. 08	MT
Nicox to Receive US Patent Extension for Latanoprostene Bunod	Jan. 31	MT
Nicox SA Receives Confirmation of 5-Year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA	Jan. 31	CI
Nicox: sales up 29% in 2023	Jan. 25	CF
Nicox's Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 Compared to Lumigan	Dec. 14	CI
Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-20	CI
Nicox's New Drug Application for Eye Drop Medicine Gets Priority Review Status in China	23-04-28	MT
Nicox Set for Euronext Growth Paris Transfer	23-04-26	MT
Global markets live: ASML, Netflix, United Airlines, Morgan Stanley, Tesla...	23-04-19
Nicox Jumps 28% as Chinese Partner Files New Drug Application for Eye Drop	23-04-14	MT
Nicox SA Announces New Drug Application Submission for ZERVIATE in China	23-04-14	CI
Global markets live: UBS, Berkshire Hathaway, First Republic Bank, Goldman Sachs...	23-03-20
Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-19	CI
Nicox S.A. Reports Net Revenue Results for the Fourth Quarter and Full Year of 2022	23-01-18	CI
Nicox Plans to Move Listing to Euronext Growth Paris	23-01-09	MT
Nicox Falls 5% After Raising $10 Million Via Private Placement	22-11-22	MT
Nicox S.A. Outlines Future Development and Partnering Plans for Ncx 470 in Glaucoma	22-11-07	CI
Nicox's Investigational Once-daily Drug Lowers Eye Pressure in Late-stage Study	22-10-31	MT
Nicox S.A. Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470	22-10-31	CI
Nicox Completes Late-stage Study of Eye Disease Drug	22-09-19	MT
Nicox S.A. Announces Last Patients Complete Final Visit in Ncx 470 Phase 3 Mont Blanc Glaucoma Trial	22-09-19	CI
Nicox S.A.(ENXTPA:COX) dropped from S&P Global BMI Index	22-09-19	CI

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The Company is also conducting research on NCX 1728 in retinal conditions. NCX 4251 for topical ocular application for dry eye disease is being developed by Nicox's licensed partner Ocumension Therapeutics in China and is available for partnering elsewhere. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow Health, Inc. in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets."

Sector

Pharmaceuticals

Calendar

2024-05-05 - Association for Research in Vision and Ophthalmology Meeting - Corinna Galli

More about the company

Income Statement Evolution

More financial data

Ratings for Nicox SA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.381 EUR

Average target price

1 EUR

Spread / Average Target

+162.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
NICOX SA	-13.80%	19.97M
KYOWA KIRIN CO. LTD.	+10.08%	9.12B
SK BIOPHARMACEUTICALS CO., LTD.	-17.63%	4.8B
YUHAN CORPORATION	+0.73%	3.8B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+16.55%	3.72B
INDIVIOR PLC	+27.76%	2.58B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-26.11%	2.36B
BETTA PHARMACEUTICALS CO., LTD.	-30.09%	2.11B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+7.15%	1.86B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals

Nicox SA

Equities

ALCOX

FR0013018124

Pharmaceuticals

Nicox S.A. Reports Revenue Results for the First Quarter of 2021

Latest news about Nicox SA

Chart Nicox SA

Company Profile

Income Statement Evolution

Ratings for Nicox SA

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals